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Objective: Lung ischemia–reperfusion injury is associated with impaired gas exchange from increased edema
formation and surfactant inactivation. Surfactant replacement therapy is believed to improve gas exchange and
lung function, but its effect on inflammation is less well understood. We therefore examined the effects of exog-
enous surfactant on inflammatory and apoptotic factors in the lung in a rat model of lung ischemia–reperfusion
injury.
Methods: The left lung in rats was subjected to ischemia for 120 minutes and reperfusion for as long as 240
minutes. Sham-treated animals underwent sham surgery and mechanical ventilation for equivalent times. Rats
received porcine surfactant or saline solution intratracheally either before or just after ischemia. Lungs were
analyzed histopathologically and for expressions of inducible nitric oxide, cytokines, and caspase-3.
Results: Lung ischemia–reperfusion injury resulted in worse lung histopathologic characteristics than in sham-
operation animals. At 2 hours of reperfusion, lung ischemia–reperfusion injury animals showed increased
pulmonary caspase-3 expression. Moreover, lung ischemia–reperfusion injury resulted in inducible nitric oxide
expression at all time points. Exogenous surfactant resulted in less inflammatory cell infiltration and edema in
the lungs relative to saline-treated animals. Surfactant decreased activated caspase-3 expression and increased
inducible nitric oxide expression relative to saline-treated animals. At 4 hours of reperfusion, surfactant
increased interleukin 6 and 10 expressions in the lung.
Conclusion: This study showed a significant improvement in lung histologic characteristics after surfactant ther-
apy, accompanied by reduced apoptosis and increased anti-inflammatory cytokine levels. Interestingly, surfactant
therapy also increased pulmonary inducible nitric oxide expression.
General Thoracic Surgery van Putte et alLung ischemia–reperfusion injury (LIRI) is a significant
cause of early morbidity and mortality after lung transplan-
tation. LIRI is characterized by acute hypoxic respiratory
failure resulting from noncardiogenic pulmonary edema
caused by an increased permeability of the alveolar capillary
barrier. Several data from experimental studies for acute
lung injury suggest that exogenous surfactant can improve
lung function and outcome by decreasing edema formation,
reducing protein leakage, and improving histopathologic
state.1-6 Interestingly, surfactant also has shown strong
immunomodulatory properties in vitro. For instance, surfac-
tant proteins A and D are able to regulate toll-like receptors,
resulting in altered production of inflammatory mediators.7
Furthermore, surfactant preparations containing surfactants
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stimulated human alveolar macrophages and peripheral
blood monocytes in vitro.8-10 Despite the clear effects of
surfactant in vitro, data on the immunomodulatory effects
of surfactant in vivo are scarce and contradictory. For
instance, Vreugdenhil and colleagues11 showed exogenous
surfactant to restore lung function, but with no effect on
proinflammatory cytokine expression in the lung. In line
with these data, several groups showed in different models
that exogenous surfactant had no effect on proinflammatory
mediators.12-14 On the other hand, Stamme and coworkers15
reported increased tumor necrosis factor a and interleukin
(IL) 6 production in ventilation-induced lung injury,
whereas Rasaiah and colleagues16 reported decreased tumor
necrosis factor a and IL-6 production in sepsis-induced lung
injury. Our aim in this study was to investigate the immuno-
modulatory effects of surfactant on inflammatory mediators
and apoptosis in a rat model of LIRI.
MATERIALS AND METHODS
Animals
Male Sprague-Dawley rats, obtained from Harlan (Harlan Netherlands
BV, Horst, The Netherlands), were used. Animals were treated in accor-
dance with the Animal Welfare Act and in compliance with the Guide for
the Care and Use of Laboratory Animals (www.nap.edu/catalog/5140.
html). All experiments were approved by the ethical committee of the
Erasmus Medical Center (Rotterdam, The Netherlands).rgery c April 2009
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SAbbreviations and Acronyms
IL ¼ interleukin
iNOS ¼ inducible nitric oxide
ISR ¼ ischemia, then surfactant, then reperfusion
LIRI ¼ lung ischemia–reperfusion injury
SIR ¼ surfactant, then ischemia, then reperfusion
Study Design
Eighty-four rats were anesthetized with a gas mixture (65% nitrous
oxide, 33% oxygen, and 2% isoflurane) and subsequently intubated and
mechanically ventilated (12 cm H2O peak inspiratory pressure, 4 cm H2O
positive end-expiratory pressure, 50% inspired oxygen fraction, a frequency
of 40 breaths/minute, and a ratio of inspiration to expiration time of 1:2).
Anesthesia was continued with pentobarbital (60 mg/mL), and muscle
relaxation was achieved with pancuronium bromide (2 mg/mL), both
repeated every hour.
Except for the sham-operated group, which underwent all operative
interventions but without induction of ischemia, all rats underwent 2 hours
of warm ischemia of the left lung caused by clamping of the pulmonary hi-
lum, followed by 30, 120, or 240 minutes of reperfusion (all groups n ¼ 7).
Rats were treated by intratracheal instillation of surfactant (natural porcine
surfactant, HL-10, 200 mg/kg; LEO Pharma A/S, Ballerup, Denmark) either
before (surfactant, then ischemia, then reperfusion [SIR]) or just after (ische-
mia, then surfactant, then reperfusion [ISR]) ischemia. Control rats received
saline solution intratracheally before start of ischemia. At the end of reper-
fusion, the rats were killed with an overdose of pentobarbital.
Surfactant and Surfactant Administration
Surfactant was dissolved in saline solution (45 mg/mL) and administered
intratracheally at a dose of 200 mg/kg, resulting in surfactant exposure of
both lungs.
All SIR rats received surfactant intratracheally after they were briefly
anesthetized and intubated. Three dosages (each instillation included a third
of the total volume per rat) were administered to each rat during 1 hour
before the start of ischemia. After each surfactant instillation, the animals
recovered from anesthesia while breathing spontaneously, resulting in
homogeneous distribution in both lungs. The control rats received saline
solution in the same volume and according to the same protocol as the
SIR rats. The ISR animals had surfactant instillation after 2 hours of ische-
mia. Immediately after release of the clamp at the start of reperfusion, the
whole dose of 200 mg/kg was administered intratracheally in a single instil-
lation. After recruitment, pressure-controlled ventilation was temporarily
augmented to achieve homogeneous distribution of surfactant.
Western Blotting
Total lung homogenates were prepared with tissue lysis buffer and a pro-
tease inhibitor cocktail (Sigma-Aldrich Co, St Louis, Mo). From 10 to 30 mg
protein was separated by either 10% or 15% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis and analyzed for inducible nitric oxide
(iNOS) expression (Santa Cruz Biotechnology, Inc, Santa Cruz, Calif)
and cleaved caspase-3 expression (Santa Cruz), respectively, by immuno-
blot analysis. b-Actin (Santa Cruz) was used as loading control. Immunore-
activity was detected by enhanced chemiluminescence (ECL; Amersham
plc, Little Chalfont, UK).
Cytokines
IL-6 (BD Biosciences, San Jose, Calif) and IL-10 (BD Biosciences)
cytokine levels were measured in total lung homogenates by enzyme-linked
immunosorbent assay according to manufacturer protocol.The Journal of Thoracic and CLung Histologic Study
Lung tissue specimens were fixed in formalin, dehydrated, cleared, and
embedded in paraffin. Specimens were cut into 8-mm serial sections and
stained with hematoxylin and eosin.
Statistical Analysis
All data are presented as mean  SE. All parameters were analyzed by
1-way analysis of variance, followed by Bonferroni post hoc test.
RESULTS
Histologic Study
Lung specimens of the control animals were characterized
by severe pathologic changes at all reperfusion time points.
At 30 minutes of reperfusion, atelectasis and thickened alve-
olar septa that had been infiltrated by inflammatory cells
were observed (Figure 1). Alveolar edema and bleeding ap-
peared to be more prominent at 240 minutes of reperfusion.
Interestingly, both surfactant groups (SIR and ISR) only
showed slightly thickened alveolar septa, slight alveolar
edema, and minimal infiltration of inflammatory cells at all
reperfusion time points relative to saline-treated animals
(Figure 1).
Inflammatory Mediators
Western blot analysis revealed iNOS expression in the
control group at all reperfusion time points, whereas iNOS
was undetectable in the sham-operated group (P<.001; Fig-
ure 2). Surfactant treatment decreased iNOS expression at
30 minutes of reperfusion in both the SIR and ISR groups
(P<.001). Interestingly, iNOS expression was significantly
increased at 120 minutes of reperfusion in the SIR group rel-
ative to the control group (P<.001), and a delayed response
was observed in the ISR group, resulting in higher levels of
iNOS at 240 minutes of reperfusion (P< .01; Figure 2).
IL-6 expression in the control group remained stable at all
reperfusion time points, being significantly higher at 240
minutes of reperfusion relative to the sham-operated group
(P< .05; Figure 3). Surfactant treatment increased IL-6
expression relative to control at all time points only in the
control group (P< .05). In the ISR group, IL-6 was only
elevated relative to control at 240 minutes of reperfusion
(P< .01; Figure 3).
IL-10 expression in the control group dropped signifi-
cantly as a function of time, being significantly lower at
240 minutes of reperfusion relative to the sham-operated
group (P<.05; Figure 4). After surfactant treatment, signif-
icantly higher IL-10 expressions were observed at 240 min-
utes of reperfusion in both the SIR and ISR groups (P<.01
SIR, P< .001 ISR; Figure 4).
Apoptosis
Control animals showed increased levels of the proapop-
totic marker cleaved caspase-3 relative to the sham-operated
group only at 120 minutes of reperfusion (P< .001). At 30
and 240 minutes of reperfusion, caspase-3 levels were similarardiovascular Surgery c Volume 137, Number 4 825
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SFIGURE 1. Representative paraffin sections of rat lung tissue stained with hematoxylin and eosin as function of time for sham-operated group (sham), control
group (salineþIþR), and groups with surfactant administered before (surfactantþIþR) and after (IþsurfactantþR) ischemia. Original magnification3200.to those in the sham-operated group (Figure 5). Surfactant re-
duced cleaved caspase-3 expression at 120 minutes of reper-
fusion relative to control (P<.001 SIR and ISR). Also at 30
and 240 minutes of reperfusion, caspase-3 levels were dimin-
ished in both surfactant groups (SIR and ISR) relative to both
the control and sham-operated groups (P< .05; Figure 5).
DISCUSSION
In this study, we determined the effects of exogenous sur-
factant on inflammation and apoptosis in an animal model of
LIRI. Although many studies have described the protective
effect of exogenous surfactant on lung function and outcome
in experimental models of acute lung injury,2,3,6 little is
known about the immunomodulatory effects of surfactant
in vivo. The effects of surfactant seem to depend on the ex-
perimental model, dosage, and time of administration.1,4,5
To address the time of administration, we treated rats either
before ischemia or just after ischemia. We show here that
surfactant increases IL-6 and IL-10 in the lung at 240 min-
utes after ischemia. IL-6 is a pleiotropic cytokine that can
either induce proinflammatory mediator expression or exert
cytoprotective effects, depending on the in vivo environ-
mental circumstances.17 IL-6 is transcriptionally regulated
by neutral factor kB, but at high levels IL-6 protein in turn
may limit neutral factor kB activity in a negative feedback
loop, thereby dampening the inflammatory response. We
therefore suggest that the increased IL-6 response seen after
surfactant treatment may be anti-inflammatory. This hypoth-
esis is supported by data of Farivar and colleagues,18 who
showed that recombinant IL-6 improved LIRI. Moreover,826 The Journal of Thoracic and Cardiovascular Suin a rodent model of hemorrhagic shock, exogenous IL-6
decreased lung and liver tissue injury.19
In addition to increased levels of IL-6, we also observed
augmented IL-10 expression after surfactant treatment. IL-
10 has a strong anti-inflammatory effect by limiting the
secretion of proinflammatory cytokines by macrophages
and T cells. Several studies have shown that exogenous
IL-10 attenuates experimental reperfusion injury of the in-
testine, liver, lung, and hindlimb.20-23 In this study, IL-10
decreased dramatically with time in the control animals,
whereas surfactant treatment normalized or even increased
IL-10 expression, suggesting that surfactant induces a strong
anti-inflammatory environment.
We also looked at the expression of iNOS. Baron and as-
sociates24 demonstrated that expression of iNOS in lung ep-
ithelial cells is critical for the development of lung injury and
furthermore mediates surfactant dysfunction. Some investi-
gators have suggested that increased lung apoptosis could be
one of the mechanisms through which iNOS causes lung in-
jury.25 We report that iNOS was specifically upregulated in
the control group, whereas it was not upregulated in the
sham-operated group, which supports the notion that iNOS
is an important mediator during lung injury. In line with
this finding, we observed increased cleaved caspase-3
expression in the control group. Interestingly, 2 and 4 hours
after ischemia iNOS was strongly upregulated by surfactant
either before (SIR) or after (ISR) ischemia. The enhanced
expression of iNOS after surfactant treatment was not asso-
ciated with enhanced apoptosis, because at all time points
both surfactant treatment schedules significantly decreasedrgery c April 2009
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tions that iNOS expression may be involved in antiapoptotic
pathways, depending on cell type, stimulus, and duration (as
reviewed by Mehta25). In our study, the early expression of
iNOS, 30 minutes after ischemia, was significantly downre-
gulated by surfactant treatment. We therefore speculate that
early expression of iNOS triggers the proinflammatory re-
sponse, whereas longer periods of iNOS expression trigger
antiapoptotic pathways. This speculation is supported by
the data of Mikawa and coworkers,26 who showed that selec-
tive inhibition of iNOS with ONO-1714 improved lung ox-
ygenation, pulmonary edema, and leukocyte sequestration
when administered before or within 2 hours after induction
FIGURE 3. Interleukin 6 (IL-6) concentrations as function of time. Inter-
leukin 6 levels were determined by standard enzyme-linked immunosorbent
assay. *P< .05; **P< .01; N ¼ 7 per group. sham; salineþ IþR;
surfactantþ IþR; IþsurfactantþR.
FIGURE 2. Inducible nitric oxide (iNOS) concentrations as function of
time. Inducible nitric oxide expression levels were assessed in total cell
ysates resolved by 10% sodium dodecyl sulfate polyacrylamide gel electro-
phoresis and analyzed by Western blot. Data (mean  SEM) were normal-
ized to b-actin expression and depicted as percentage of control values
(black bars). Insets are representative Western blots depicting immunode-
tectable inducible nitric oxide. **P< .01; ***P< .001; N ¼ 7 per group.
sham; salineþ IþR; surfactantþ IþR; IþsurfactantþR.The Journal of Thoracic and Cof acute lung injury but not if administered 3 or 4 hours after
induction.
Interestingly, comparison of the effects of surfactant ad-
ministered before and after ischemia on the parameters mea-
sured showed a time-dependent relationship. The delayed
response in the ISR group is explained by the time sequence
of the experimental setting. It is known that the reperfusion
period plays a significantly more important role in causing
injury than does the ischemic period.27 This might explain
the equivalent responses, but with different time kinetics,
FIGURE 4. Interleukin 10 (IL-10) concentrations as function of time.
Interleukin 10 levels were determined by standard enzyme-linked immuno-
sorbent assay. *P<.05; **P<.01; ***P<.001; N¼ 7 per group. sham;
salineþ IþR; surfactantþ IþR; IþsurfactantþR.
FIGURE 5. Effect of lung ischemia–reperfusion injury on cleaved cas-
pase-3 expression as function of time. Cleaved caspase-3 expression levels
were assessed in total cell lysates resolved by 15% sodium dodecyl sulfate
polyacrylamide gel electrophoresis and analyzed by Western blot. Data
(mean  SEM) were normalized to b-actin expression and depicted as per-
centage of values in sham-operated group. Insets are representative Western
blots depicting immunodetectable cleaved caspase-3. *P< .05; **P< .01;
***P<.001; N¼ 7 per group. sham; salineþIþR; surfactantþI
þR; IþsurfactantþR.ardiovascular Surgery c Volume 137, Number 4 827
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From a clinical point of view, it may be interesting for future
studies to analyze the effect on ischemia–reperfusion injury
of surfactant administered after the onset of reperfusion.
Interestingly, however, Struber and colleagues28 showed
that exogenous surfactant instilled in donor lungs before
retrieval had protective effects on posttransplant surfactant
function and on clinical outcome.28
In conclusion, we have shown surfactant to have pleiotro-
pic effects during LIRI. First, surfactant therapy efficiently
improves lung architecture. Second, surfactant results in
anti-inflammation, accompanied by decreased apoptosis.
Finally, surfactant decreases the short-term iNOS expression
but increases the long-term iNOS expression. Surfactant
replacement therapy thus may provide a good approach to
treat LIRI in patients, although more studies are warranted
to further delineate the long-term effects of surfactant and
the mechanisms involved.
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